loading page

Usefulness of E7 mRNA in HPV16-positive women to predict the risk of progression to HSIL/CIN2+
  • +6
  • Cristina Marti,
  • Lorena Marimon,
  • Ariel Glickman,
  • Carla Henere,
  • Adela Saco,
  • Natalia Rakislova,
  • Aureli Torné,
  • Jaume Ordi,
  • Marta del Pino
Cristina Marti
Institute Clinic of Gynaecology, Obstetrics, and Neonatology, Hospital Clinic
Author Profile
Lorena Marimon
Hospital Clínic de Barcelona
Author Profile
Ariel Glickman
Institute Clinic of Gynaecology, Obstetrics, and Neonatology, Hospital Clinic
Author Profile
Carla Henere
Institute Clinic of Gynaecology, Obstetrics, and Neonatology, Hospital Clinic
Author Profile
Adela Saco
Hospital Clínic de Barcelona
Author Profile
Natalia Rakislova
Hospital Clínic de Barcelona
Author Profile
Aureli Torné
Hospital Clinic de Barcelona Institut Clinic de Ginecologia Obstetricia i Neonatologia
Author Profile
Jaume Ordi
Hospital Clínic de Barcelona
Author Profile
Marta del Pino
Institute Clinic of Gynaecology, Obstetrics, and Neonatology, Hospital Clinic - Institut dInvestigacions Biomediques August Pi i Sunyer (IDIBAPS), University of Barcelona, Barcelona,
Author Profile

Abstract

Objective: To evaluate whether E7 mRNA can predict the risk of progression in women with HPV16 infection. Design: prospective observational study Setting: Tertiary university hospital Population: A cohort of 139 women referred to colposcopy for an abnormal screening result fulfilling the following inclusion criteria: 1) a positive test result confirming HPV16 infection; 2) a biopsy sample with a histological diagnosis of absence of lesion or low-grade SIL/CIN grade1 (LSIL/CIN1); 3) no previous HPV vaccination; 4) no pregnancy; and 5) no previous cervical treatments; and 6) no immunosuppression. Methods: At the first visit all women underwent a cervical sample for liquid-based cytology, HPV testing and genotyping, and HPV16 E7 mRNA analysis and a colposcopy with at least one colposcopy-guided biopsy. Follow-up visits were scheduled every six months. In each control a liquid-based Pap smear, HPV testing, as well as a colposcopy examination with biopsy if necessary were performed. Main outocome measures: Histological diagnosis of HSIL/CIN2+ at any time during follow-up Results: E7 mRNA expression was positive in 55/127 (43.3%) women included in the study and seven (12.7%) progressed to HSIL/CIN2+. In contrast, only 1/72 (1.4%) women with no HPV16 E7 mRNA expression progressed (p=0.027). HPV16 E7 mRNA expression was associated with a 10-fold increased risk of progression (HR 10.0; 95%CI 1.2-81.4). Conclusions: HPV16 E7 mRNA could be useful for risk stratification of women with HPV16 infection in whom a HSIL/CIN2+ has been ruled out.